Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute Identifier:
First received: November 29, 2011
Last updated: June 29, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2016
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)